These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10585700)

  • 21. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug pipeline: 1Q12.
    Mak C
    Nat Biotechnol; 2012 May; 30(5):383. PubMed ID: 22565954
    [No Abstract]   [Full Text] [Related]  

  • 23. Path to approval proves rocky for copycat biodrugs.
    Wadman M
    Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
    [No Abstract]   [Full Text] [Related]  

  • 24. Amgen asks judge for speedy ruling in patent case.
    Nephrol News Issues; 1999 Dec; 13(12):14. PubMed ID: 11984928
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 26. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 27. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 28. Biotech's new colossus. Move over, Big Pharma. Amgen boasts better growth.
    Stipp D
    Fortune; 2002 Apr; 145(8):144-6, 148, 150. PubMed ID: 11961884
    [No Abstract]   [Full Text] [Related]  

  • 29. Botanical drugs: a future for herbal medicines.
    Li W
    J Contemp Health Law Policy; 2002; 19(1):117-49. PubMed ID: 12733224
    [No Abstract]   [Full Text] [Related]  

  • 30. Biotechnology and patent term extension issues.
    Raines L
    Food Drug Law J; 1999; 54(2):237-40. PubMed ID: 11758579
    [No Abstract]   [Full Text] [Related]  

  • 31. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug approval and pharmaceutical pricing.
    Kozma CM
    Manag Care Interface; 2002 Feb; 15(2):65-6. PubMed ID: 11875964
    [No Abstract]   [Full Text] [Related]  

  • 34. Sandoz sues FDA over delay in first biogeneric approval.
    Fox JL
    Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
    [No Abstract]   [Full Text] [Related]  

  • 35. The brave new world of healthcare e-commerce.
    Hirsch R
    J Cardiovasc Manag; 1999; 10(3):13-4. PubMed ID: 10557912
    [No Abstract]   [Full Text] [Related]  

  • 36. FDA and EMEA pool scientific advice.
    Katsnelson A
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract]   [Full Text] [Related]  

  • 37. Vouchers for FDA priority reviews.
    Spatz ID
    Health Aff (Millwood); 2006; 25(4):1184; author reply 1184-5. PubMed ID: 16835203
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug pipeline: Q111.
    Peng W
    Nat Biotechnol; 2011 May; 29(5):383. PubMed ID: 21552231
    [No Abstract]   [Full Text] [Related]  

  • 39. Biotechnology. Mixed reactions to merger.
    Gershon D
    Nature; 1990 Feb; 343(6260):681. PubMed ID: 2304541
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.